Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

Overview of attention for article published in OncoTargets and therapy, July 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

Programmed death-1 inhibitors as treatment for other subtypes of lymphomas not recommended in the guidelines: Real-world data from a single center in China

Preprint in Research Square (February 2024)

Checkpoint inhibition in hematologic malignancies

Article in Frontiers in Oncology (October 2023)

Advances and challenges of immunotherapies in NK/T cell lymphomas

Article in iScience (October 2023)